Phaseline

Companies › Fore Biotherapeutics

Fore Biotherapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
plixorafenib
Serine/threonine-protein kinase B-raf inhibitor
BRAFPhase 2Cancer Harboring BRAF AlterationsDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05503797plixorafenibPhase 2Cancer Harboring BRAF AlterationsOncologyDec 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

BRAF (1)

Companies with the same targets

Roche Pfizer Pierre Fabre Medicament Novartis Haisco Pharmaceutical Group Erasca Shanghai Kechow Pharma Day One Biopharmaceuticals Ipsen Hanmi Pharmaceutical Company

Companies built like this

NanoEcho Syncromune Galecto Biotech VSPharmTech BPGbio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.